Last reviewed · How we verify
NCT06617572
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
trial testing Non-conforming afamitresgene autoleucel in Synovial Sarcoma. Available.
Quick facts
| Lead sponsor | USWM CT, LLC |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 11 locations across United States |
Drugs / interventions tested
- Non-conforming afamitresgene autoleucel
Conditions studied
- Synovial Sarcoma — all drugs for Synovial Sarcoma →
- Myxoid Liposarcoma — all drugs for Myxoid Liposarcoma →
Sponsor
USWM CT, LLC — full company profile →
Who can join
18 and older, any sex, with Synovial Sarcoma or Myxoid Liposarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06617572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Synovial Sarcoma
Currently open trials in the same condition.
- NCT06083883 — Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 · Phase 1 · recruiting
- NCT05642455 — SPEARHEAD-3 Pediatric Study · Phase 1, PHASE2 · recruiting
- NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
- NCT04995003 — HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma · Phase 1 · recruiting
- NCT04420975 — Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma · Phase 1 · active not recruiting
Other USWM CT, LLC trials
Trials by the same sponsor.
- NCT05642455 — SPEARHEAD-3 Pediatric Study · Phase 1, PHASE2 · recruiting
- NCT05601752 — ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURP · Phase 2 · active not recruiting
- NCT06703346 — Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive · Phase 2 · active not recruiting
- NCT03967223 — Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a · Phase 2 · active not recruiting
- NCT04044859 — ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Pos · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06617572 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by USWM CT, LLC
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing